Pub Date : 2022-05-08DOI: 10.37191/mapsci-2582-385x-4(2)-108
G. Slater
Articular cartilage, a highly specialized and unique tissue, is capable of dispersing immense compression loads and almost eradicating friction in diarthrodial joints. This paper investigates the structure, nutrition, and repair of cartilage to further understand the unique tissue. A breakthrough in cartilage repair and regeneration is discussed.
{"title":"Articular Cartilage - A Literature Review","authors":"G. Slater","doi":"10.37191/mapsci-2582-385x-4(2)-108","DOIUrl":"https://doi.org/10.37191/mapsci-2582-385x-4(2)-108","url":null,"abstract":"Articular cartilage, a highly specialized and unique tissue, is capable of dispersing immense compression loads and almost eradicating friction in diarthrodial joints. This paper investigates the structure, nutrition, and repair of cartilage to further understand the unique tissue. A breakthrough in cartilage repair and regeneration is discussed.","PeriodicalId":325610,"journal":{"name":"Journal of Regenerative Biology and Medicine","volume":"162 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124534426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-31DOI: 10.37191/mapsci-2582-385x-4(2)-107
B. Gayathri
Background: NESEM ™/S2013, 500mg capsules were prepared by NPP Ltd containing the extracted Secondary Plant Metabolites (eSPMs): S40, S54, S55. These eSPMs were identified to be biologically active using human cells expressing cancer specific monooxygenase enzymes. Extensive bioavailability assessments were carried out. An optimized blend was encapsulated in 500mg, size zero, two-piece, hard shell, vegetarian capsules (Vcaps). (Notes: NESEM™’s are produced through the shikimate pathway by natural elicitation mechanisms; NESEM™ is an acronym for Naturally Elicited Specifically Extracted Molecules). It has been demonstrated in the past studies that NESEMTM/S2013s are phyto nutrients classified as phytoalexins that function through multiple mechanisms. One of the mechanisms is the intrinsic metabolism performed by CYP1B1, a universal cancer marker resulting in disturbances of cell cycling processes triggering apoptosis. There is limited availability of these phytonutrients in our diet due to modern day agricultural practices and food processing. Phytoalexins are produced as a way of defense mechanism, in response to infection or attack by predators. The purpose of this investigation is determining the effect of NESEM™/S2013 on Quality of Life (QoL) and survival in tandem to routine cancer therapy in malignancies of the Head & Neck, GIT, Ovary, Breast and Lung. Patients and methods: This study was a two-arm randomized controlled trial with a cohort of 102 patients. The patients presented with malignancies of Head & Neck, Lung, Breast, GIT, and Ovary. The study subjects in the two groups were randomized to either receive chemotherapy, radiotherapy and surgery or a combination of two or more therapies. Both the groups were given Vitamin C and B complex. The test group along with the above received NESEM™/S2013 (three capsules of 500 mg each of NESEM™/S2013 500mg was given as leader/loading dose for a month followed by two capsules of 500 mg each of NESEM™/S2013 till discontinuation or death). Minus the NESEM™/S2013, the control group was treated same as the test group. Results: In the Head & Neck Cancer patients, the mean overall survival (OS) was significant, p=0.0441. In the test arm, average OS was 15.91 ±10.73 months compared to 8.0 ± 5.83 months in the control group. This represents a 99% increase in survivability for the NESEM™/S2013 arm. In subjects with lung cancer, the average OS in the test group was 8.708± 9.006 months compared to 2.292 ±1.484 months in the control group. The average OS was significant, p=0.0234. This represents a 280% increase in survivability for the NESEM™/S2013 arm. In patients with cancer of GIT, the mean OS in the NESEM™/S2013 arm was 10.000 ± 10.317 months compared to was 3.550 ± 3.700 months in the control arm which was significant (p=0.0792). This represents a 182% increase in survivability for the NESEM™/S2013 arm. In patients with ovarian cancer, the average survival was 17.63 ± 7.19 months in the NESEM™/S2013
{"title":"Effect Of NESEM™/s2013 In Indian Population Undergoing Conventional Treatment For The Malignancies Of The Head & Neck, Git, Ovary, Breast And Lung As An Adjunct","authors":"B. Gayathri","doi":"10.37191/mapsci-2582-385x-4(2)-107","DOIUrl":"https://doi.org/10.37191/mapsci-2582-385x-4(2)-107","url":null,"abstract":"Background: NESEM ™/S2013, 500mg capsules were prepared by NPP Ltd containing the extracted Secondary Plant Metabolites (eSPMs): S40, S54, S55. These eSPMs were identified to be biologically active using human cells expressing cancer specific monooxygenase enzymes. Extensive bioavailability assessments were carried out. An optimized blend was encapsulated in 500mg, size zero, two-piece, hard shell, vegetarian capsules (Vcaps). (Notes: NESEM™’s are produced through the shikimate pathway by natural elicitation mechanisms; NESEM™ is an acronym for Naturally Elicited Specifically Extracted Molecules).\u0000\u0000It has been demonstrated in the past studies that NESEMTM/S2013s are phyto nutrients classified as phytoalexins that function through multiple mechanisms. One of the mechanisms is the intrinsic metabolism performed by CYP1B1, a universal cancer marker resulting in disturbances of cell cycling processes triggering apoptosis. There is limited availability of these phytonutrients in our diet due to modern day agricultural practices and food processing. Phytoalexins are produced as a way of defense mechanism, in response to infection or attack by predators. The purpose of this investigation is determining the effect of NESEM™/S2013 on Quality of Life (QoL) and survival in tandem to routine cancer therapy in malignancies of the Head & Neck, GIT, Ovary, Breast and Lung.\u0000\u0000Patients and methods: This study was a two-arm randomized controlled trial with a cohort of 102 patients. The patients presented with malignancies of Head & Neck, Lung, Breast, GIT, and Ovary. The study subjects in the two groups were randomized to either receive chemotherapy, radiotherapy and surgery or a combination of two or more therapies. Both the groups were given Vitamin C and B complex. The test group along with the above received NESEM™/S2013 (three capsules of 500 mg each of NESEM™/S2013 500mg was given as leader/loading dose for a month followed by two capsules of 500 mg each of NESEM™/S2013 till discontinuation or death). Minus the NESEM™/S2013, the control group was treated same as the test group.\u0000\u0000Results: In the Head & Neck Cancer patients, the mean overall survival (OS) was significant, p=0.0441. In the test arm, average OS was 15.91 ±10.73 months compared to 8.0 ± 5.83 months in the control group. This represents a 99% increase in survivability for the NESEM™/S2013 arm. In subjects with lung cancer, the average OS in the test group was 8.708± 9.006 months compared to 2.292 ±1.484 months in the control group. The average OS was significant, p=0.0234. This represents a 280% increase in survivability for the NESEM™/S2013 arm. In patients with cancer of GIT, the mean OS in the NESEM™/S2013 arm was 10.000 ± 10.317 months compared to was 3.550 ± 3.700 months in the control arm which was significant (p=0.0792). This represents a 182% increase in survivability for the NESEM™/S2013 arm. In patients with ovarian cancer, the average survival was 17.63 ± 7.19 months in the NESEM™/S2013 ","PeriodicalId":325610,"journal":{"name":"Journal of Regenerative Biology and Medicine","volume":"83 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124116284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-31DOI: 10.37191/mapsci-2582-385x-4(2)-106
P. Sewell
A single adult female human was treated with AAV hTERT gene transfer therapy on two separate occasions 5 years apart. Follow-up is 5.8 years. The first dose administered on 9.16.2015 consisted of a total intravenous dose of 3e15 AAV hTERT. The second dose administered on 9.24.2020 consisted of a total intravenous dose of 3e15 AAV hTERT. Before and after each therapy and periodically in between the doses, Human Leucocyte telomere analysis was performed. The initial telomere length measurements collected on 9.15.2015 at the initiation of the AAV hTERT gene transfer therapy demonstrated a baseline average telomere length of 6.71kb which corresponded to a telomere percentage relative to age and population at the 30th percentile. The most recent telomere length measurements collected on 7.13.2021 demonstrated an average telomere length of 8.94kb which corresponded to a telomere percentage relative to age and population at the 89th percentile. The results demonstrate the progressive lengthening of the recipient’s telomeres from 6.71kb to 8.94kb despite advancing 5.8 years in chronological age. Associated age as related to telomere length (also known as biological age) was calculated and compared to chronological age. Initially on 9.15.2015, and prior to the first AAV hTERT gene transfer therapy, the associated age was calculated to be 62 years. The latest telomere analysis dated 7.13.2021 demonstrated a calculated associated age of 25 years. This decrease in associated, or biological age, decreased at a rate of 5.3 years per year of chronological age advancement.
{"title":"Systemic Human Htert Aav Gene Transfer Therapy And The Effect On Telomere Length And Biological Age, A Case Report","authors":"P. Sewell","doi":"10.37191/mapsci-2582-385x-4(2)-106","DOIUrl":"https://doi.org/10.37191/mapsci-2582-385x-4(2)-106","url":null,"abstract":"A single adult female human was treated with AAV hTERT gene transfer therapy on two separate occasions 5 years apart. Follow-up is 5.8 years. The first dose administered on 9.16.2015 consisted of a total intravenous dose of 3e15 AAV hTERT. The second dose administered on 9.24.2020 consisted of a total intravenous dose of 3e15 AAV hTERT. Before and after each therapy and periodically in between the doses, Human Leucocyte telomere analysis was performed. The initial telomere length measurements collected on 9.15.2015 at the initiation of the AAV hTERT gene transfer therapy demonstrated a baseline average telomere length of 6.71kb which corresponded to a telomere percentage relative to age and population at the 30th percentile. The most recent telomere length measurements collected on 7.13.2021 demonstrated an average telomere length of 8.94kb which corresponded to a telomere percentage relative to age and population at the 89th percentile. The results demonstrate the progressive lengthening of the recipient’s telomeres from 6.71kb to 8.94kb despite advancing 5.8 years in chronological age. Associated age as related to telomere length (also known as biological age) was calculated and compared to chronological age. Initially on 9.15.2015, and prior to the first AAV hTERT gene transfer therapy, the associated age was calculated to be 62 years. The latest telomere analysis dated 7.13.2021 demonstrated a calculated associated age of 25 years. This decrease in associated, or biological age, decreased at a rate of 5.3 years per year of chronological age advancement.","PeriodicalId":325610,"journal":{"name":"Journal of Regenerative Biology and Medicine","volume":"310 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132182067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-31DOI: 10.37191/mapsci-2582-385x-4(1)-103
Wanyonyi Kennedy Mukhwana
Previous studies which helped researchers to understand embryonic development revealed multiple aspects of differentiated of human somatic cells into various types of cells. Human induced pluripotent stem cells (iPSCs) are somatic cells that are reprogrammed using certain factors that possesses pluripotent property that leads to self-proliferation and/or differentiation into various other cell types. The recent advancements using induced pluripotent stem cells have opened multiple avenues of research related to therapies. This has led to an enormous interest among scientists regarding its application ranging from regenerative medicine to modeling diseases. For example, Parkinson’s disease, Alzheimer’s disease among others could be treated with iPSC therapy or replacement tissues. In this review, we discuss the importance of iPSCs in the clinical perspective of treatment and management of disease.
{"title":"The Importance Of Human Induced Pluripotent Stem Cells In Neurodegenerative Disorders","authors":"Wanyonyi Kennedy Mukhwana","doi":"10.37191/mapsci-2582-385x-4(1)-103","DOIUrl":"https://doi.org/10.37191/mapsci-2582-385x-4(1)-103","url":null,"abstract":"Previous studies which helped researchers to understand embryonic development revealed multiple aspects of differentiated of human somatic cells into various types of cells. Human induced pluripotent stem cells (iPSCs) are somatic cells that are reprogrammed using certain factors that possesses pluripotent property that leads to self-proliferation and/or differentiation into various other cell types. The recent advancements using induced pluripotent stem cells have opened multiple avenues of research related to therapies. This has led to an enormous interest among scientists regarding its application ranging from regenerative medicine to modeling diseases. For example, Parkinson’s disease, Alzheimer’s disease among others could be treated with iPSC therapy or replacement tissues. In this review, we discuss the importance of iPSCs in the clinical perspective of treatment and management of disease.","PeriodicalId":325610,"journal":{"name":"Journal of Regenerative Biology and Medicine","volume":"3 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130819578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-15DOI: 10.37191/mapsci-2582-385x-4(2)-105
Minh Phuong Vu
Background: The Nucleophosmin 1 gene mutation (NPM1mut) is considered a favorable clinical outcome in patients with acute myeloid leukemia (AML) with normal chromosome, and this outcome may be reduced with the presence of an internal tandem repeat of the Fms-like tyrosine kinase 3 gene (FLT3-ITD). However, the effect of NPM1mut on patients with acute promyelocytic leukemia (APL) remains unclear. Our objective was to analyze the prognostic effect of the NPM1mut gene and the FLT3-ITD gene in patients with APL. Methods: Sixty patients with new APL diagnoses underwent RT-PCR detection of the NPM1mut and FLT3-ITD genes, and accepted treatment with ATRA and chemotherapy. The presence and combinations of genotypes were compared in association with overall survival (OS) and progression- free survival (PFS) outcome. Results: Twenty- eight patients had positive FLT3-ITD with a rate of 46.7%, nine had positive NPM1mut with a rate of 15%. Patients with FLT3-ITD positive have worse OS and PFS compared to FLT3-ITD negative (p=0.027; 0.008, respectively), but there were no statistically significant differences in OS, PFS between the groups: NPM1mut positive and NPM1mut negative (p=0.209; 0.352, respectively), NPM1mut positive/FLT3-ITD positive and NPM1mut negative/FLT3-ITD positive (p=0.235; 0.444, respectively), NPM1mut positive/FLT3-ITD negative and NPM1mut negative/FLT3-ITD negative (p=0.376; 0.324, respectively). Conclusions: The FLT3-ITD gene confers a poor prognosis in patients with acute promyelocytic leukemia, but the NPM1mut gene had no effect on efficacy and did no change the prognostic value of FLT3- ITD.
{"title":"The Prognostic Effect Of The NPM1 Mutation And The FLT3-ITD Genes In Acute Promyelocytic Leukemia","authors":"Minh Phuong Vu","doi":"10.37191/mapsci-2582-385x-4(2)-105","DOIUrl":"https://doi.org/10.37191/mapsci-2582-385x-4(2)-105","url":null,"abstract":"Background: The Nucleophosmin 1 gene mutation (NPM1mut) is considered a favorable clinical outcome in patients with acute myeloid leukemia (AML) with normal chromosome, and this outcome may be reduced with the presence of an internal tandem repeat of the Fms-like tyrosine kinase 3 gene (FLT3-ITD). However, the effect of NPM1mut on patients with acute promyelocytic leukemia (APL) remains unclear. Our objective was to analyze the prognostic effect of the NPM1mut gene and the FLT3-ITD gene in patients with APL.\u0000\u0000Methods: Sixty patients with new APL diagnoses underwent RT-PCR detection of the NPM1mut and FLT3-ITD genes, and accepted treatment with ATRA and chemotherapy. The presence and combinations of genotypes were compared in association with overall survival (OS) and progression- free survival (PFS) outcome.\u0000\u0000Results: Twenty- eight patients had positive FLT3-ITD with a rate of 46.7%, nine had positive NPM1mut with a rate of 15%. Patients with FLT3-ITD positive have worse OS and PFS compared to FLT3-ITD negative (p=0.027; 0.008, respectively), but there were no statistically significant differences in OS, PFS between the groups: NPM1mut positive and NPM1mut negative (p=0.209; 0.352, respectively), NPM1mut positive/FLT3-ITD positive and NPM1mut negative/FLT3-ITD positive (p=0.235; 0.444, respectively), NPM1mut positive/FLT3-ITD negative and NPM1mut negative/FLT3-ITD negative (p=0.376; 0.324, respectively).\u0000\u0000Conclusions: The FLT3-ITD gene confers a poor prognosis in patients with acute promyelocytic leukemia, but the NPM1mut gene had no effect on efficacy and did no change the prognostic value of FLT3- ITD.","PeriodicalId":325610,"journal":{"name":"Journal of Regenerative Biology and Medicine","volume":"40 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130030410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-02DOI: 10.37191/mapsci-2582-385x-4(1)-104
G. Slater
Minimally invasive image guided surgery and regenerative technologies have rapidly developed requiring changes in post-operative management protocols. With such a variety of options available for patients and varying ideas on which product is best suited for each procedure, practitioners play in important role in optimizing patient care when prescribing solutions. Function, aesthetics, and ease of mobility play key roles in patient acceptance of orthotic devices and determine the success of a product and recovery journey. This paper aims to investigate commonly utilized options for various foot and ankle conditions and compare their applications, advantages, and disadvantages. By analyzing available options, knowledge can be gained to create an optimized modular product that takes advantage of the best features of existing devices and offers a complete solution for every patient.
{"title":"Current Concepts Review: Orthotics In Post-operative Foot And Ankle Surgery","authors":"G. Slater","doi":"10.37191/mapsci-2582-385x-4(1)-104","DOIUrl":"https://doi.org/10.37191/mapsci-2582-385x-4(1)-104","url":null,"abstract":"Minimally invasive image guided surgery and regenerative technologies have rapidly developed requiring changes in post-operative management protocols. With such a variety of options available for patients and varying ideas on which product is best suited for each procedure, practitioners play in important role in optimizing patient care when prescribing solutions. Function, aesthetics, and ease of mobility play key roles in patient acceptance of orthotic devices and determine the success of a product and recovery journey. This paper aims to investigate commonly utilized options for various foot and ankle conditions and compare their applications, advantages, and disadvantages. By analyzing available options, knowledge can be gained to create an optimized modular product that takes advantage of the best features of existing devices and offers a complete solution for every patient.","PeriodicalId":325610,"journal":{"name":"Journal of Regenerative Biology and Medicine","volume":"13 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122166933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01DOI: 10.37191/mapsci-2582-385x-4(1)-101
G. Slater
Recent developments in surgical techniques have led to new methods to treat ankle arthritis and perhaps produce a better effect on joint function and gait improvement. The indications for total ankle replacement, ankle fusion, or distraction arthroplasty in the management of ankle arthritis are controversial. The aim of this study is to evaluate different approaches with an overview of the literature. Core tip: Ankle arthritis is a common debilitating chronic disease that is not only present in the geriatric population, but also younger populations. The main method to treat end stage arthritis is ankle fusion. Ankle replacement is currently improving in popularity. Both treatment options manage end stage arthritis. It is important to consider the role of distraction arthroplasty in the context of these two other well accepted treatments. Here we examine the literature from 1941 to 2020 considering our own experience and the growing role regenerative techniques and biologics.
{"title":"A Review Of Distraction Arthroplasty Vs Ankle Arthrodesis Vs Ankle Replacement","authors":"G. Slater","doi":"10.37191/mapsci-2582-385x-4(1)-101","DOIUrl":"https://doi.org/10.37191/mapsci-2582-385x-4(1)-101","url":null,"abstract":"Recent developments in surgical techniques have led to new methods to treat ankle arthritis and perhaps produce a better effect on joint function and gait improvement. The indications for total ankle replacement, ankle fusion, or distraction arthroplasty in the management of ankle arthritis are controversial. The aim of this study is to evaluate different approaches with an overview of the literature. \u0000\u0000Core tip: Ankle arthritis is a common debilitating chronic disease that is not only present in the geriatric population, but also younger populations. The main method to treat end stage arthritis is ankle fusion. Ankle replacement is currently improving in popularity. Both treatment options manage end stage arthritis. It is important to consider the role of distraction arthroplasty in the context of these two other well accepted treatments. Here we examine the literature from 1941 to 2020 considering our own experience and the growing role regenerative techniques and biologics.","PeriodicalId":325610,"journal":{"name":"Journal of Regenerative Biology and Medicine","volume":"79 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124851466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01DOI: 10.37191/mapsci-2582-385x-4(1)-100
G. Slater
The management of Achilles tendon rupture has remained a contentious topic. Non-operative management has gained popularity due to the problems associated with traditional open repair. This paper outlines a minimally invasive approach, that intends to minimise the rate of re-rupture, and is not associated with the more inconvenient complications of open repair.
{"title":"A Technique Update For A Minimally Invasive Operative Approach To Achilles Tendon Repair","authors":"G. Slater","doi":"10.37191/mapsci-2582-385x-4(1)-100","DOIUrl":"https://doi.org/10.37191/mapsci-2582-385x-4(1)-100","url":null,"abstract":"The management of Achilles tendon rupture has remained a contentious topic. Non-operative management has gained popularity due to the problems associated with traditional open repair. This paper outlines a minimally invasive approach, that intends to minimise the rate of re-rupture, and is not associated with the more inconvenient complications of open repair.","PeriodicalId":325610,"journal":{"name":"Journal of Regenerative Biology and Medicine","volume":"35 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128224971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01DOI: 10.37191/mapsci-2582-385x-4(1)-102
V. Gallicchio
Huntington's disease is a progressive genetic neurodegenerative disease that causes the loss of medium spiny neurons in the brain's striatum. Huntington's is caused by a trinucleotide repeat, specifically CAG base pairs. The CAG repeat can cause a mutant form of the huntingtin protein to be produced. The exact mode in which the mutant protein causes the disease is still uncertain. However, patients with Huntington's experience a plethora of motor and cognitive issues. Currently, there is no cure for Huntington's; only means of symptom management exist. Stem cells are being studied as a therapeutic option in HD treatment as well as models of disease pathology. Various types of stem cells have been analyzed for their varying attractive qualities. Embryonic, neural, mesenchymal, adipose, and induced pluripotent stem cells have been studied using animal models. In this article, we will examine the cultivation, attributes, and any drawbacks of each of the mentioned stem cell types as means of therapeutic devices for HD.
{"title":"Stem Cells Use As A Therapy For Huntington's Disease","authors":"V. Gallicchio","doi":"10.37191/mapsci-2582-385x-4(1)-102","DOIUrl":"https://doi.org/10.37191/mapsci-2582-385x-4(1)-102","url":null,"abstract":"Huntington's disease is a progressive genetic neurodegenerative disease that causes the loss of medium spiny neurons in the brain's striatum. Huntington's is caused by a trinucleotide repeat, specifically CAG base pairs. The CAG repeat can cause a mutant form of the huntingtin protein to be produced. The exact mode in which the mutant protein causes the disease is still uncertain. However, patients with Huntington's experience a plethora of motor and cognitive issues. Currently, there is no cure for Huntington's; only means of symptom management exist. Stem cells are being studied as a therapeutic option in HD treatment as well as models of disease pathology. Various types of stem cells have been analyzed for their varying attractive qualities. Embryonic, neural, mesenchymal, adipose, and induced pluripotent stem cells have been studied using animal models. In this article, we will examine the cultivation, attributes, and any drawbacks of each of the mentioned stem cell types as means of therapeutic devices for HD.","PeriodicalId":325610,"journal":{"name":"Journal of Regenerative Biology and Medicine","volume":"22 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125799785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-12-17DOI: 10.21203/rs.3.rs-1179251/v1
Queendaline Ibenegbu Obiajulu, C. B. Ugwu, C. Ibenegbu, Helen Onyinye Muojekwu, N. Odionye, A. N. Ngwu, Okafor Blessing Ijeoma, Nwankwo Amaka Loretta, O. L. Aniaku, R. I. Enebechi, Chukwunta Regina Ugochi
This study is on bridging the gap in learning differences among biology students using 4MAT Application Techniques. We carried out the study in Abakaliki, Nigeria. We adopted a quasi-experimental design for the study. We used 138 SS-II students from two schools. Two hypotheses were tested. We analyzed the data using descriptive statistics and Hierarchical Analysis of covariance (ANCOVA). The results showed that there was a significant main effect of instructional method on students' achievement in biology F (7, 121) = 12.654, p =.000, partial η2 =.39; there was no significant main effect of gender on students' achievement in biology F (1, 121) = 1.240, p =.268, partial η2 =.004. We highlighted the educational implications of the findings and the recommendations. We also made some limitations of the study and suggestions for further studies.
本研究旨在探讨如何运用4MAT应用技术，弥合生物系学生在学习上的差异。我们在尼日利亚的Abakaliki进行了这项研究。本研究采用准实验设计。我们使用了来自两所学校的138名SS-II学生。测试了两个假设。我们使用描述性统计和分层协方差分析(ANCOVA)对数据进行分析。结果表明:教学方法对学生生物成绩有显著的主效应F (7,121) = 12.654, p =。000，偏η2 = 0.39;性别对学生生物成绩无显著主效应F (1,121) = 1.240, p =。268，偏η2 = 0.004。我们强调了研究结果和建议的教育意义。并提出了本研究的局限性和进一步研究的建议。
{"title":"Bridging the Gap in Learning Differences Among Biology Students Using 4 Mode Application Techniques","authors":"Queendaline Ibenegbu Obiajulu, C. B. Ugwu, C. Ibenegbu, Helen Onyinye Muojekwu, N. Odionye, A. N. Ngwu, Okafor Blessing Ijeoma, Nwankwo Amaka Loretta, O. L. Aniaku, R. I. Enebechi, Chukwunta Regina Ugochi","doi":"10.21203/rs.3.rs-1179251/v1","DOIUrl":"https://doi.org/10.21203/rs.3.rs-1179251/v1","url":null,"abstract":"\u0000 This study is on bridging the gap in learning differences among biology students using 4MAT Application Techniques. We carried out the study in Abakaliki, Nigeria. We adopted a quasi-experimental design for the study. We used 138 SS-II students from two schools. Two hypotheses were tested. We analyzed the data using descriptive statistics and Hierarchical Analysis of covariance (ANCOVA). The results showed that there was a significant main effect of instructional method on students' achievement in biology F (7, 121) = 12.654, p =.000, partial η2 =.39; there was no significant main effect of gender on students' achievement in biology F (1, 121) = 1.240, p =.268, partial η2 =.004. We highlighted the educational implications of the findings and the recommendations. We also made some limitations of the study and suggestions for further studies.","PeriodicalId":325610,"journal":{"name":"Journal of Regenerative Biology and Medicine","volume":"43 7","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"120858551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：